A pharmaceutical dosage form suitable for oral administration comprising a solid dispersion of at least one HIV protease inhibitor, at least one first pharmaceutically acceptable water-soluble polymer (A), at least one second pharmaceutically acceptable water-soluble polymer (B), and optionally at least one pharmaceutically acceptable surfactant,wherein the at least one first pharmaceutically acceptable water-soluble polymer (A) has a glass transition temperature (Tg) of at least 50°C and is present in an amount of 10% to 49% by weight of the dosage form and is not polyvinylpyrrolidone (PVP) or hydroxypropyl methylcellulose (HPMC), and wherein the at least one second pharmaceutically acceptable water-soluble polymer (B) has a Tg of less than 50°C.